What to know about Johnson & Johnson COVID-19 vaccine side effects
The Johnson & Johnson (Janssen) COVID-19 vaccine is a viral-vector vaccine that, like all vaccines, can cause side effects. Most are mild to moderate and resolve within a few days. Serious effects are rare but important to understand. This overview covers what to expect, how the vaccine compares to others, and how to monitor your health after vaccination.
How viral-vector vaccines can cause side effects
Vector vaccines use a harmless, non-replicating virus to deliver instructions to your cells so they can make the SARS-CoV-2 spike protein and train your immune system. Reactions are usually signs that your immune system is responding. Most side effects are short-lived and are not a sign of ongoing infection or long-term harm.
Very common, common, and rare reactions
Health authorities use standardized frequency terms to help people understand what to expect. Very common means an event affects 1 in 10 or more people; common means 1 in 100 to 1 in 10; rare means 1 in 1,000 to 1 in 10,000; very rare means fewer than 1 in 10,000. These estimates are derived from clinical trials and post-authorization monitoring at scale.
Very common side effects (≥1 in 10)
- Pain at the injection site
- Headache
- Fatigue
- Muscle aches
- Chills
- Fever
These typically begin within a few hours to two days after vaccination and resolve within two to three days. Rest, fluids, and over-the-counter pain relievers such as acetaminophen or ibuprofen can help, unless contraindicated for you.
Timing and duration of local and systemic reactions
Local reactions, such as soreness and swelling at the injection site, are most common in the first 48 hours. Systemic symptoms, such as fever and fatigue, tend to peak around day two and improve by day three. These patterns are similar across protein subunit and mRNA platforms, though some studies report slightly higher rates of certain systemic symptoms with viral-vector vaccines.
Common side effects (≥1 in 100 to
- Nausea
- Diarrhea
- Swollen lymph nodes
- Redness or warmth at the injection site
- Itching at the injection site
These reactions are usually self-limited and resolve without specific treatment. Swollen lymph nodes, particularly in the armpit or neck on the same side as the injection, can occur as the immune system activates and may last a week or slightly longer.
Rare and serious side effects
Rare but serious events identified for viral-vector COVID-19 vaccines include Thrombosis with Thrombocytopenia Syndrome (TTS), anaphylaxis, and, very rarely, capillary leak syndrome. These are monitored continually in real-world data to ensure that benefits continue to outweigh risks.
Thrombosis with Thrombocytopenia Syndrome (TTS)
TTS involves unusual blood clots combined with low platelet counts. It occurs primarily in younger adults, particularly women, and typically appears within one to two weeks after vaccination. The absolute risk is low. Health agencies have reviewed this risk carefully and recommend that people discuss individual risk factors with their clinician.
Anaphylaxis
Anaphylaxis is a severe allergic reaction that can occur after any vaccine. It is rare and treatable when recognized promptly. Vaccination sites are equipped to manage this condition immediately. People with a history of severe allergic reactions to ingredients in the vaccine may be advised to avoid it or be monitored longer after dosing.
Other rare considerations
- Myocarditis and pericarditis: more associated with mRNA vaccines, but reported rarely after viral-vector vaccines
- Capillary leak syndrome: very rare, closely monitored, and not causally established at population level for COVID-19 vaccines in all regions
- Thrombocytopenia without thrombosis: may be evaluated as part of TTS case definitions
If you experience concerning symptoms after vaccination—such as severe or worsening shortness of breath, chest pain, leg swelling, or persistent severe headache—seek medical care promptly and mention your recent vaccination.
Very rare and long-term considerations
Ongoing, broad-cohort studies and active safety surveillance are used to detect extremely rare events and to characterize long-term outcomes. To date, large-scale reviews have not identified credible evidence that authorized COVID-19 vaccines, including the Johnson & Johnson vaccine, cause severe long-term health conditions in otherwise healthy individuals. Clinical trials and post-authorization studies continue to inform guidance.
Who may be at higher risk and when to seek care
Certain groups may be at higher risk for severe COVID-19 and may be advised to consult their clinician about timing and choice of vaccine. After any vaccination, seek immediate care for symptoms such as difficulty breathing, swelling of the face or throat, rapid heartbeat, or severe persistent symptoms. People with a history of serious allergic reactions should discuss vaccination plans with their clinician.
Comparisons with other platforms
Different vaccine platforms have slightly different side effect profiles and logistical characteristics. Understanding these differences can help contextualize expectations, though all authorized vaccines in the U.S. have been shown to prevent severe disease, hospitalization, and death.
| Attribute | Johnson & Johnson (viral-vector) | mRNA (Moderna/Pfizer) | Protein subunit (Novavax) |
|---|---|---|---|
| Platform | Modified adenovirus vector delivering spike protein instructions | Lipid nanoparticle-encased mRNA encoding spike protein | Recombinant spike protein plus adjuvant |
| Dosing | 1 primary dose (with option of a booster) | 2 primary doses (with boosters recommended) | 2–3 doses depending on age and immunocompromise (primary series and boosters) |
| Common local side effects | Injection site pain, swelling | Injection site pain, erythema, swelling | Injection site pain, erythema, swelling |
| Common systemic side effects | Headache, fatigue, myalgia, fever, chills | Headache, fatigue, myalgia, fever, chills | Headache, fatigue, myalgia, fever, chills |
| Rare serious event most associated | TTS (lower incidence with newer formulations and updated recommendations) | Myocarditis/pericarditis (higher in younger males, especially after dose 2) | Rare reports of myocarditis, anaphylaxis |
| Typical onset of common side effects | Within hours to 2 days; peak ~day 2 | Within hours to 2 days; peak ~day 2 | Within hours to a few days; peak ~day 2–3 |
| Duration of common side effects | Most resolve in 2–3 days | Most resolve in 2–3 days | Most resolve in 2–3 days |
Risk versus benefit in real-world context
COVID-19 infection carries significant risks of acute illness, long COVID, hospitalization, and death. Vaccination, including with viral-vector platforms, substantially reduces these risks. Health authorities continue to monitor vaccine safety globally and update recommendations to reflect the latest evidence on benefits and risks. For most people, the benefits of vaccination in preventing severe outcomes outweigh the risks of known side effects.
Practical steps after vaccination
- Expect common, mild reactions and plan for short-term rest as needed.
- Use cool compresses for injection site discomfort and stay hydrated.
- Keep a vaccination card and note the date and lot number if available.
- Report any unexpected or severe reactions to your clinician and to vaccine safety systems.
- Stay up to date with boosters and follow the latest guidance from health authorities.
When to seek medical attention
Seek immediate medical care for signs of anaphylaxis (difficulty breathing, swelling of the face or throat), symptoms of TTS (severe headache with persistent vomiting, visual changes, or neurological symptoms, accompanied by abdominal pain or leg swelling), or severe chest pain or shortness of breath. For less urgent concerns, contact your primary care provider or local health department.
Reliable sources for ongoing updates
- Centers for Disease Control and Prevention (CDC)
- U.S. Food and Drug Administration (FDA)
- World Health Organization (WHO)
- Your state or local health department
For personalized medical advice, including vaccine product selection and timing, consult your clinician or a qualified healthcare professional.
Key takeaways on Johnson & Johnson COVID-19 vaccine side effects
- Most side effects are mild to moderate and resolve within a few days.
- Serious events such as TTS are rare and predominantly reported in younger women; the absolute risk is low.
- All COVID-19 vaccines authorized in the U.S. reduce the risk of severe disease, hospitalization, and death.
- Individual risk factors and preferences should be discussed with a clinician.
- Staying up to date with boosters and following public health guidance remain important over time.
Ongoing safety monitoring and real-world data reviews support current guidance. This information is intended to provide a balanced, evidence-based overview to support informed decisions.